Jaap Bremer

T: +31 70 376 06 25
E: jaap.bremer@barentskrans.nl
View Jaap Bremer on LinkedIn

Jaap’s practice focuses on Intellectual Property litigation, in particular with respect to patents, trademarks and advertising. Jaap has extensive experience in infringement and invalidity litigation, as well as in parallel import, anti-counterfeiting and customs enforcement matters, particularly for clients in the pharma & life sciences, food & beverage and consumer products industries. He also regularly advises clients in non-contentious matters, including negotiation and drafting of licence and coexistence agreements. Jaap is internationally recognised as a specialist in both patent law and trademark and copyright law. In Chambers 2020, he was the only lawyer in the Netherlands to be ranked in both categories.

Selected directory listings

Jaap is an outstanding IP lawyer and a top expert in software-related IP matters. He has always achieved excellent results for us. He has always demonstrated the utmost professionalism, dedication and commitment to the client. He is extremely strategic, sophisticated and business-oriented and has always taken the time to fully understand our business goals, objectives, products and strategy. In summary, Jaap is a top-notch IP lawyer and a trusted advisor with an outstanding track record. The level and quality of his legal services are unmatched and he is a pleasure to work with.’ – Legal 500, 2022

‘I really appreciate the fact that he doesn’t take a ‘one size fits all’ approach; he takes the time to listen to you and he figures out what the client wants achieved.’ – Chambers Europe, 2022

‘Department head Bremer’s personable approach, eye for detail and deep patent knowledge are appreciated by those seeking to defend intricate inventions.’ – IAM Patents 1000, 2021

‘Jaap Bremer is a standout trade mark lawyer, combining legal knowledge with a practical, commercial application and also Jaap Bremer: hands-on, practical advice combined with an open mind to handle matters, leading to solutions that the business can always work with. ‘Experienced litigator and negotiator.’ – Legal 500, 2021

Jaap Bremer is active on both trade mark and patent disputes. His adroit manner of communication is underlined by clients, one informing of his ‘ability to quickly grasp the essence of a case, which he can then explain in easy-to-understand language accurately to the client and the judges.’ – Chambers Europe, 2021

Professional activities

  • Member of Editorial Board EPLAW Patent Blog
  • Member of the International Trademark Association (INTA)
  • Member of various professional associations, including EPLAW, PTMG, LES, BMM, VFenR, VvRr and MARQUES
  • Member of Vereniging Intellectuele Eigendom Proces Advocaten (VIEPA)

Recently from this specialist

Pharma update | Court of Appeal overturns ruling District Court in Astrazeneca v Menzis

In an earlier Pharma Update, we reported on the judgment of the District Court of The Hague of 14 October 2020 in which AstraZeneca AB (“AstraZeneca”) was ordered to pay damages to health insurer Menzis Zorgverzekeraar NV (“Menzis”) for having enforced a patent that was later invalidated against a generic company.   This judgment has now
Read more ›

Telecoms update | PI judge dismisses Ericsson’s anti-anti-suit injunction claim against Apple

On 16 December 2021 the PI Judge of the District Court of The Hague (“PI Judge”) rendered a judgment in PI proceedings initiated by Telefonaktiebolaget LM Ericsson (“Ericsson”) against Apple Retail Netherlands B.V., Apple Benelux B.V., Apple Inc., Apple Distribution International and Apple Sales International Ltd (“Apple et al.”). Ericsson is the patent proprietor of
Read more ›

Pharma update – 17 August 2021 | Provisions judge denies preliminary order to carve out indications from marketing authorisation adalimumab biosimilar

In his decision of 16 July 2021 (published 5 August 2021) the Provisions Judge of the District Court of Amsterdam denied a preliminary order claimed by AbbVie Biotechnology Ltd (“AbbVie”) against Alvotech HF, Alvotech Swiss AG and Stada Arzneimittel AG (“Stada”) (collectively: “Alvotech et al.”) to carve-out AbbVie’s patented indications prior to launching their biosimilar
Read more ›
More from this specialist